论文部分内容阅读
急性髓细胞白血病(AML)的发病率随着年龄的增加而上升。老年AML患者对标准化疗的反应性较年轻人差,体现在完全缓解率低、无复发生存率低、总体生存时间短。依据近年来的临床研究应该从老年AML患者独特的生物学特性和身体心理等方面因素考虑,选取个体化治疗方案,并且在恰当的时机实施以改善预后。目前,抗CD33单抗、法尼酰基转移酶抑制剂、新型核苷类似物、FMS样酪氨酸激酶3抑制剂、甲基转移酶抑制剂以及靶向治疗新药在老年AML患者中的应用正处于临床研究阶段,为治疗提供了新的方向。
The incidence of acute myeloid leukemia (AML) increases with age. Older AML patients respond less well to standard chemotherapy than younger patients, reflecting a low rate of complete remission, a low rate of relapse-free survival and a short overall survival. Based on the recent years of clinical research should be based on the unique biological characteristics of elderly patients with AML and physical and other factors to consider, select individualized treatment options, and implemented at the right time to improve the prognosis. Currently, anti-CD33 monoclonal antibody, farnesyl transferase inhibitors, novel nucleoside analogs, FMS-like tyrosine kinase 3 inhibitors, methyltransferase inhibitors and targeted therapies are new drugs in elderly patients with AML positive In the clinical research stage, provides a new direction for the treatment.